A panelist discusses how identifying steroid-dependent or steroid-refractory (SR) graft-vs-host disease (GVHD) requires careful clinical monitoring, with the determination typically made when patients ...

A panelist discusses how steroid therapy remains the cornerstone of acute graft-vs-host disease (GVHD) treatment, with ...

Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my recommendation for SNDX.

All patients received myeloablative conditioning. The trial’s primary endpoint measured survival free of cGVHD, a possible transplant complication in which the donor's immune cells attack the ...

Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the ...

Orca-T significantly improved cGVHD-free survival compared to allo-HSCT, with a 78% vs 38% rate at one year. The study reported a 94% overall survival rate for Orca-T, with no new safety concerns ...

It’s usually taken once per day. Imbruvica is used to treat the following conditions in adults: It’s also used to treat cGVHD in some children ages 1 year and older. The active ingredient in ...

The study met its primary endpoint, with Orca-T demonstrating a statistically significant improvement in survival free of moderate-to-severe chronic graft versus host disease (cGvHD). At one year, the ...